Authors
Loading...
Observational study shows loss of butyrate producers worsens progression-free survival in multiple myeloma, suggesting microbiome as a therapeutic target.
Aleman et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: